Original Research ARTICLE
Magnetic Iron Sulfide Nanoparticles as Thrombolytic Agents for Magnetocaloric Therapy and Photothermal Therapy of Thrombosis
- 1Xinjiang Medical University, Urumqi, China
- 2Department of Vascular Surgery, Karamay Central Hospital, Karamay, China
- 3Material Science and Engineering School, Donghua University, Shanghai, China
- 4Department of Vascular Surgery, The People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China
Non-invasive removal of thrombosis is a difficult problem in clinical vascular disease. Herein, we reported magnetic hyperthermia combined photothermal therapy for celiac vein thrombosis using Fe3S4 nanoparticles as thrombolytic agents under the stimulation of a near infrared (NIR) laser and an external alternating magnetic field (AMF). Fe3S4 nanoparticles showed excellent magnetothermal conversion performance under the continuous stimulation of an AMF and very good photothermal conversion performance under the irradiation of a NIR laser. Moreover, Fe3S4 nanoparticles exhibited a synergistic thermal conversion effect under the co-stimulation of NIR and AMF. In addition, the Fe3S4 nanoparticles possess the ability for magnetic resonance (MR) imaging with the transverse relaxivity (r2) is up to 53.1 mM−1 s−1. Finally, we, for the first time, proved the Fe3S4 nanoparticles as a promising thrombolytic agent for both photothermal thrombolytic capacity and magnetothermal thrombolytic ability. Our work provides the insight of hyperthermia for removal of the thrombosis.
Cardiovascular disease is one of the main causes of harm to human health (Mackman, 2008; Engelmann and Massberg, 2013). Because the blood vessels are aging and the blood vessel wall is damaged, it is easy to form the thromboses in the blood vessel, and it is also more likely to suffer from diseases such as hypertension and arteriosclerosis. Surgery and chemotherapy are still the main treatment options for thrombosis. Surgical treatment causes great pain to the patient's body; chemotherapy is non-targeting and belongs to systemic administration, which has great side effects (Voros et al., 2015). Traditional treatments often treat known thrombi, but may cause new problems for blood vessels. Older people with thrombosis often do not dare to use thrombolytic drugs. Therefore, it is of great significance to develop an efficient and accurate thrombosis treatment system for non-invasive and precise treatment of thrombosis.
Clinically approved thrombolytic agents are characterized by short half-life, short blood flow life and damage to local bleeding (Hacke et al., 2008; Derex and Nighoghossian, 2009). Nanoparticles have proven to be promising diagnostic agents for the treatment of a variety of diseases and have relatively long blood circulation agents (Vogel and Venugopalan, 2003; Mahmoudi et al., 2011; Li et al., 2017). At present, it has been reported that hyperthermia can achieve a good thrombolytic effect (Voros et al., 2015; Wang X. et al., 2017). Hyperthermia methods include photothermal therapy and magnetic hyperthermia (Dai et al., 2019). Photothermal therapy is the treatment through heat generated by near-infrared (NIR) light-induced photothermal reagents (Fang et al., 2012; Zhang et al., 2013; Chen et al., 2014; Li et al., 2014, 2015, 2017). Wang et al. prove that heat generated by the photothermal effect of gold can achieve the purpose of thrombolysis (Wang X. et al., 2017). Magnetic hyperthermia is a way in which a magnetothermal conversion reagent generates heat to treat a disease under the action of an external alternating magnetic field (AMF) (Wang F. et al., 2017; Li et al., 2018; Dai et al., 2019). The magnetocaloric effect of iron oxide has been shown to accelerate the dissolution of blood clots in Voros et al.' report (Voros et al., 2015). However, there are more or less defects in the way of thrombolysis. In the photothermal treatment, due to the poor penetration of light, it is impossible to treat deep thrombus, such as celiac vein thrombosis. In the case of iron oxide magnetothermal treatment of thrombus, it causes certain side effects due to the long-term presence of iron oxide in the body. Therefore, there is a great of necessary and importance to adjust the current strategy for treating thrombosis to treat thrombosis.
Fe3S4 nanoparticles have similar properties to iron oxide (Liu et al., 2014). It has been revealed that Fe3S4 nanoparticles have a very good magnetocaloric effect which could be used in magnetic hyperthermia for deep thrombosis (Guan et al., 2018; Moore et al., 2019). Moreover, Fe3S4 nanoparticles have been shown to degrade rapidly in vivo (Guan et al., 2018). Therefore, Fe3S4 nanoparticles show great potential for the magnetic hyperthermia for deep thrombosis. Herein, we reported hyperthermia for celiac vein thrombosis using Fe3S4 nanoparticles as a thrombolytic reagent under the stimulation of a NIR laser and an AMF. Fe3S4 nanoparticles show a synergistic thermal transition effect under the co-action of a NIR laser and an AMF. In addition, the Fe3S4 nanoparticles possess the ability for magnetic resonance (MR) imaging with the transverse relaxivity (r2) is up to 53.1 mM−1 s−1. Finally, we, for the first time, proved the Fe3S4 nanoparticles as a promising thrombolytic agent for magnetic hyperthermia for celiac vein thrombosis.
Results and Discussion
Synthesis and Characterization of Fe3S4 Nanoparticles
Hydrophilic Fe3S4 nanoparticles were synthesized via a simple hydrothermal method by reaction the FeSO4 with L-Cysteine in water at 220°C for 20 h. During the preparation, the polyvinylpyrrolidone (PVP) was added into the reaction as surface ligand to improve their biocompatibility. Thus, the Fe3S4 nanoparticles are capped by PVP (demonstrated by FTIR, Figure S1) and hydrophilic, and can be used as thrombolytic agents without any further modification. As shown in Figure 1A, transmission electron microscopy (TEM) image demonstrated that the as-prepared products were highly dispersible nanoparticles. The size of NCs was found to be 17.7 nm based on the TEM images (Figure S2). More microstructure information can be achieved from high resolution TEM (Figure 1B). It shows an interplanar spacing of 0.298 nm, which can be indexed to (220) planes of greigite structured Fe3S4. As shown in Figure 1C, X-ray diffraction (XRD) pattern of the products could be well-matched with that of greigite structured Fe3S4 (JCPDS file no.: 16-0713), indicating that we obtained pure greigite structured Fe3S4 with high crystallinity. X-ray photoelectron spectroscopy (XPS) revealed the composition and element state of the as-prepared products (Figure S3). It showed that the products mainly contain Fe and S elements with no other impurities. We analyzed the valency state of Fe in Fe3S4 nanoparticles. Figure 1D shows Fe 2p spectrum for the Fe3S4 nanoparticles. It was demonstrated that there was a mixed Fe oxidation state, i.e., Fe2+ and Fe3+ (Guan et al., 2018), indicating a defect structure in Fe3S4 nanoparticles. According to the above results, it can be concluded that the pure Fe3S4 nanoparticles with high crystallinity was successfully formed.
Figure 1. (A) TEM image of as-prepared Fe3S4 nanoparticles. (B) High resolution TEM image of Fe3S4 nanoparticles. (C) XRD pattern of Fe3S4 nanoparticles. (D) High resolution XPS spectra of Fe in Fe3S4 nanoparticles.
Magnetocaloric Conversion Performance of Fe3S4 Nanoparticles
Figures 2A,B shows the magnetocaloric conversion performance of Fe3S4 nanoparticles. Under the continuous simulation of AMF (4.2 × 109 A m−1 s−1), the temperature of Fe3S4 nanoparticles with a concentration of 0.5 mg/mL can increase by 12.8°C, while the temperature change of pure water is not obvious. When the concentration is increased to 1.0 mg/mL, the temperature of Fe3S4 nanoparticle dispersion can be raised by 20°C which is high enough to dissolve thrombus. Figure 2C shows the thermal imaging of pure water and Fe3S4 nanoparticles (1.0 mg/mL) under the action of an AMF for 5 min, respectively. As we can see from Figure 2D, a high contrast image was obtained. These results indicated that Fe3S4 nanoparticles showed an excellent magnetocaloric conversion performance.
Figure 2. (A) Temperature change of the Fe3S4 nanoparticles in water at varied concentrations of Fe2+ (i.e., 0, 0.5, and 1.0 mg/mL) as a function of magnetic field action time. (B) Plot of temperature change over 300s vs. the concentration of Fe3S4 nanoparticles. Thermal imaging of (C) pure water and (D) Fe3S4 nanoparticles (1.0 mg/mL) under the action of an AMF for 5 min.
Photothermal Conversion Performance of Fe3S4 Nanoparticles
We also measured the UV-vis absorbance spectrum of the Fe3S4 nanoparticles, which is important for photothermal performance. From Figure 3A, we can see that the Fe3S4 nanoparticles showed a strong absorption in the NIR region from 700 to 1,000 nm, resulted from the defect structure in Fe3S4 nanoparticles. Then varied concentrations (0–0.5 mg/mL) of Fe3S4 nanoparticles were exposed to an 808 nm (0.33 W cm−2) laser to evaluate the photothermal effect. As expected, the Fe3S4 nanoparticles showed a good photothermal conversion performance with concentration-dependent photothermal effect (Figure 3B). Fe3S4 nanoparticles with a concentration at 0.5 mg/mL, the temperature can increase by about 30°C, while the temperature of pure water showed little change. The photothermal performance of Fe3S4 nanoparticles ensured the potential of Fe3S4 nanoparticles as a thrombolytic reagent.
Figure 3. (A) UV-vis absorbance spectrum of the Fe3S4 nanoparticles. (B) Temperature change of the Fe3S4 nanoparticles in water at varied concentrations (i.e., 0, 0.125, 0.25, and 0.5 mg/mL) as a function of the irradiation time of an 808 nm laser (0.33 W cm−2).
Synergistic Thermal Conversion Effect
To test the synergistic thermal conversion effect of Fe3S4 nanoparticles, Fe3S4 nanoparticles (500 ppm, 100 μL) was assessed under the simultaneous stimulation including a NIR (808 nm, 0.33 W cm−2) laser and an AMF (4.2 × 109 A m−1 s−1) for 5 min. Temperature change was recorded by a thermal imaging camera. It was found that the temperature elevation can reach 37.1°C under the co-stimulation of NIR and AMF (Figure 4A). From Figure 4B, we can see that the temperature change from the co-stimulation of NIR and AMF was much higher the that from the single stimulation of NIR or AMF, indicating a synergistic thermal conversion effect.
Figure 4. (A) Temperature change of Fe3S4 nanoparticles under co-stimulation of NIR and AMF for 5 min. (B) Comparison of the temperature change from the indicated conditions. Fe3S4 nanoparticles: 0.5 mg/mL; NIR: 808 nm, 0.33 W cm−2; AMF: 4.2 × 109 A m−1 s−1.
Combined Therapy of Thrombotic in vitro
Due to the excellent thermal conversion performance of Fe3S4 nanoparticles, we measured the in vitro thrombolytic capacity of Fe3S4 nanoparticles under an 808 nm (0.33 W cm−2) laser and/or an AMF (4.2 × 109 A m−1 s−1). Thrombosis was obtained 1 week after ligation of the abdominal vena cava in mice using the surgical suture. A thrombus block was placed in a 20 mL glass vial followed by a 5 mL Fe3S4 nanoparticle solution. Finally, it was irradiated by an 808 nm (0.33 W cm−2) laser and/or an AMF (4.2 × 109 A m−1 s−1) for in vitro thrombolysis. As a control, the thrombus block in another bottle containing nanoparticle solution wasn't stimulated by NIR laser. It showed that the thrombus can be partially dissolved under the stimulation of NIR or AMF combined with Fe3S4 nanoparticles. Moreover, when co-stimulated by NIR and AMF, the thrombus was almost disappeared (Figure S4). However, the thrombus in the control showed little change. Therefore, Fe3S4 nanoparticles can be used as a thrombolytic agent under the stimulation of NIR or/and AMF.
MR Imaging Guided Thrombotic in vivo
Fe3S4 nanoparticles can be served for imaging guided magnetic hyperthermia of thrombosis. We established a model of deep vein thrombosis using black C57 mice, and the penetration depth of the laser did not reach the lesions. Moreover, the temperature of the hair of the C57 mice increased after laser irradiation to cause burntness. So we use magnetic hyperthermia to dissolve the thrombus. First, Fe3S4 nanoparticle' phantom images and proton T2 relaxation test at varied Fe concentrations were measured. As shown in Figure 5A, T2-weighted MR imaging signal intensity was increased with the increase of the concentration of Fe3S4 nanoparticle. The transverse relaxivity (r2) value of the CMO NCs was calculated to be 53.1 mM−1 s−1, indicating an efficient MRI contrast agent (Figure 5B). We then evaluated animal experiments on the T2-weighted MR imaging guided magnetic hyperthermia of thrombosis. From Figure 5C, we can see that the signal in thrombosis sites (left) was light white. Under the action of Fe3S4 nanoparticles combined with AMF, light white region in thrombosis sites (right) obviously decreased. Therefore, Fe3S4 nanoparticles can be served as an efficient thrombolytic agent in vivo.
Figure 5. (A) Phantom images of the Fe3S4 nanoparticles. (B) Proton T2 relaxation measurements at varied Fe concentrations (C) T2-weighted MR imaging in vivo of a mouse with celiac vein thrombosis before (left) and after (right) an intravenous injection of a solution of the Fe3S4 nanoparticles followed by the simulation of AMF.
Biomaterials must have good biocompatibility in clinical applications. Then in vivo long-term toxicity of the as-prepared Fe3S4 nanoparticles was evaluated by blood bioanalysis and hematoxylin and Eosin analysis, respectively. There was no obvious difference detected in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (Figures 6A,B), which indicated that Fe3S4 nanoparticles have good biocompatibility to the liver and heart (Zhang et al., 2018). Then histological examination analysis for main organs was performed to observe the shape and the size of cells after the intravenous injection of Fe3S4 nanoparticles at a dosage of 12 mg/kg. The organs included the heart, kidney, liver, lung, and spleen. As shown in Figure 6C, there is no tissue damage or adverse effect compared with those of control groups. This suggests that these Fe3S4 nanoparticles at the given dose are not obviously toxic.
Figure 6. Blood bioanalysis of mice in control group and Fe3S4 group at different time points (1, 3, 7, 15, and 30 days), including (A) alanine aminotransferase (ALT) and (B) aspartate aminotransferase (AST). (C) Hematoxylin and Eosin stained tissue sections from the mice to monitor the histological changes in heart, kidney, liver, lung, and spleen of the mice 1 month after a single intravenous injection of the Fe3S4 nanoparticle' solution. Scale bar: 100 μm.
It was reported that inorganic nanoparticles (quantum dots used as a model system) with relatively large sizes would accumulate in reticuloendothelial systems (RES) such as liver and spleen for long periods of time (Choi et al., 2007). Ideally, it would be the best to make Fe3S4 nanoparticles quickly excreted from the normal organs of the body, while being able to effectively accumulate and retain in lesions. A study from guan reported that the clearance of Fe3S4 nanoparticles was quickly post intravenous injection (Guan et al., 2018). We also studied the distribution and metabolism of the Fe3S4 nanoparticles, mice were intravenously injected with 12 mg·kg−1 of the Fe3S4 nanoparticles. At different intervals of time (i.e., 1, 3, 7, and 10 days, n = 3 at each time point), mice were sacrificed to obtain major organs including kidney, spleen, heart, liver, and lung. These organs were digested and solubilized. An ICP-MS analysis was used to determine Fe content in each organ. It was (Figure S5) found that the Fe3S4 nanoparticles mainly accumulate at spleen and liver, indicating that Fe3S4 nanoparticles was mainly degraded in these two organs.
In conclusion, Fe3S4 nanoparticles, as a new imaging-guided thrombolytic agent, have been successfully prepared by a simple hydrothermal route. The as-prepared Fe3S4 nanoparticles have a good dispersity and show an excellent magnetothermal conversion performance and photothermal effect, and exhibited a synergistic thermal conversion effect under the co-stimulation of NIR and AMF. They also possess an effective MR imaging in vivo. Furthermore, the in vivo toxicity results indicate their excellent biocompatibility. With the stimulation of an external AMF and a NIR laser, the Fe3S4 nanoparticles can be used as thrombolytic agents with MR imaging guided hyperthermia of thrombosis.
Synthesis of Fe3S4 Nanoparticles
One millimole of FeSO4 and 1 mmol L-cysteine were consecutively dissolved in 40 mL water. Seven hundred milligram of poly (vinyl pyrrolidone) (PVP) was then added. Then the reaction was kept at 220°C for 24 h in a stainless steel autoclave. The products were collected through centrifugation and finally washed with ethanol and deionized water for three times.
The morphology as well as the size of nanoparticles was achieved by TEM (JEOL JEM-2010F, Japan). The crystal phase of Fe3S4 nanoparticles was measured by XRD (Bruker D4). The oxidation state analysis of Fe3S4 nanoparticles was measured by X-ray photoelectron spectra (XPS, ESCA-Lab 250Xi). Concentration of Fe ions released from Fe3S4 nanoparticles was tested by ICP-AES (Leeman Laboratories Prodigy).
Measurement of Magnetocaloric Conversion Performance of Fe3S4 Nanoparticles
For the evaluation of the magnetocaloric conversion performance of Fe3S4 nanoparticles, 100 μL of Fe3S4 nanoparticles dispersed in deionized water at varied concentrations was simulated under the external AMF (4.2 × 109 A m−1 s−1). Temperature change was recorded by a thermal imaging camera.
Measurement of Photothermal Effect of Fe3S4 Nanoparticles
For the evaluation of the photothermal performance of Fe3S4 nanoparticles, 100 μL of Fe3S4 nanoparticles dispersed in deionized water at varied concentrations was exposed upon the irradiation of an 808 nm laser. Temperature change was recorded by a thermal imaging camera.
Thrombotic Animal Model
All animal experiments were approved by the Animal Ethics Committee of Karamay central hospital. 8-week-old C57 mice were anesthetized and laparotomy, the inferior vena cava was separated, and the inferior vena cava was ligated under the left renal vein with a surgical line (Kyogashima et al., 1999).
Hyperthermia of Thrombosis in vitro
To evaluate in vitro thrombolytic capacity of Fe3S4 nanoparticles under the irradiation of a NIR laser or/and AMF, thromboses was obtained 1 week after ligation of the abdominal vena cava in mice using a surgical line. A thrombus block was placed in a 20 mL glass vial followed by a 5 mL Fe3S4 nanoparticle solution. Finally, it was irradiated by an 808 nm laser or/and AMF for in vitro thrombolysis. As a control, the thrombus block in another bottle containing nanoparticle solution wasn't stimulated by the 808 nm laser or/and AMF.
MR Imaging Guided Hyperthermia of Thrombosis in vivo
The Fe3S4 nanoparticle dispersions with varied Fe concentrations (0–0.28 mM) were scanned at room temperature via the animal MR imagine scanner under a 0.5 T MRI scanner at room temperature. Before in vivo MR imaging guided magnetic hyperthermia of thrombosis, thrombosis model mouse were scanned with the same MR scanner with the same parameters to be a control. After intravenous injection with the Fe3S4 nanoparticle dispersion (100 μL, 12 mg/kg) followed by stimulation under an AMF, the thrombosis model mouse were scanned again with the MR scanner.
Histological Examination Analysis and Blood Analysis
As for the histological examination, one mouse in each group was killed under anesthesia after the indicated treatment. Then the organs included the heart, kidney, liver, lung, and spleen were harvested, and then sectioned into 4 μm slices using a conventional microtome, finally stained with H&E. The slices were examined via a microscope. Also, the blood from mice in control group and Fe3S4 group was collected to test the biocompatibility of Fe3S4 nanoparticle to major organs.
Data Availability Statement
All datasets generated for this study are included in the article/Supplementary Material.
The animal study was reviewed and approved by the Animal Ethics Committee of Karamay Central Hospital.
DF, JD, and XG designed the project. DF, QR, JL, and HD carried out the experiment and performed the experimental data analysis. DF and XC wrote the paper. All the authors contributed to discussion of the results.
This work was supported by Xinjiang Uygur Autonomous Region Natural Science Fund (2019D01A08).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmats.2019.00316/full#supplementary-material
Chen, Q., Wang, C., Zhan, Z., He, W., Cheng, Z., Li, Y., et al. (2014). Near-infrared dye bound albumin with separated imaging and therapy wavelength channels for imaging-guided photothermal therapy. Biomaterials 35, 8206–8214. doi: 10.1016/j.biomaterials.2014.06.013
Dai, C., Wang, C., Hu, R., Lin, H., Liu, Z., Yu, L., et al. (2019). Photonic/magnetic hyperthermia-synergistic nanocatalytic cancer therapy enabled by zero-valence iron nanocatalysts. Biomaterials, 219:119374. doi: 10.1016/j.biomaterials.2019.119374
Fang, W., Yang, J., Gong, J., and Zheng, N. (2012). Photo- and pH-triggered release of anticancer drugs from mesoporous silica-coated Pd@Ag nanoparticles. Adv. Funct. Mater. 22, 842–848. doi: 10.1002/adfm.201101960
Guan, G., Wang, X., Li, B., Zhang, W., Cui, Z., Lu, X., et al. (2018). “Transformed” Fe3S4 tetragonal nanosheets: a high-efficiency and body-clearable agent for magnetic resonance imaging guided photothermal and chemodynamic synergistic therapy. Nanoscale 10, 17902–17911. doi: 10.1039/C8NR06507A
Hacke, W., Kaste, M., Bluhmki, E., Brozman, M., Dávalos, A., Guidetti, D., et al. (2008). Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med. 359, 1317–1329. doi: 10.1056/NEJMoa0804656
Kyogashima, M., Onaya, J., Miyauchi, S., Arai, M., Shibata, Y., Suda, A., et al. (1999). Antithrombotic activity of avian crown dermatan sulfate. Thromb. Res. 96, 459–465. doi: 10.1016/S0049-3848(99)00138-3
Li, B., Wang, Q., Zou, R., Liu, X., Xu, K., Li, W., et al. (2014). Cu7.2S4 nanocrystals: a novel photothermal agent with a 56.7% photothermal conversion efficiency for photothermal therapy of cancer cells. Nanoscale 6, 3274–3282. doi: 10.1039/c3nr06242b
Li, B., Ye, K., Zhang, Y., Qin, J., Zou, R., Xu, K., et al. (2015). Photothermal theragnosis synergistic therapy based on bimetal sulphide nanocrystals rather than nanocomposites. Adv. Mater. Weinheim. 27, 1339–1345. doi: 10.1002/adma.201404257
Li, B., Yuan, F., He, G., Han, X., Wang, X., Qin, J., et al. (2017). Ultrasmall CuCo2S4 nanocrystals: all-in-one theragnosis nanoplatform with magnetic resonance/near-infrared imaging for efficiently photothermal therapy of tumors. Adv. Funct. Mater. 27:1606218. doi: 10.1002/adfm.201606218
Li, M., Bu, W., Ren, J., Li, J., Deng, L., Gao, M., et al. (2018). Enhanced synergism of thermo-chemotherapy for liver cancer with magnetothermally responsive nanocarriers. Theranostics 8, 693–709. doi: 10.7150/thno.21297
Mahmoudi, M., Sant, S., Wang, B., Laurent, S., and Sen, T. (2011). Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. Adv. Drug Deliv. Rev. 63, 24–46. doi: 10.1016/j.addr.2010.05.006
Voros, E., Cho, M. J., Ramirez, M., Palange, A. L., De Rosa, E., Key, J., et al. (2015). TPA immobilization on iron oxide nanocubes and localized magnetic hyperthermia accelerate blood clot lysis. Adv. Funct. Mater. 25, 1709–1718. doi: 10.1002/adfm.201404354
Wang, F., Yang, Y., Ling, Y., Liu, J., Cai, X., Zhou, X., et al. (2017). Injectable and thermally contractible hydroxypropyl methyl cellulose/Fe3O4 for magnetic hyperthermia ablation of tumors. Biomaterials 128, 84–93. doi: 10.1016/j.biomaterials.2017.03.004
Wang, X., Wei, C., Liu, M., Yang, T., Zhou, W., Liu, Y., et al. (2017). Near-infrared triggered release of uPA from nanospheres for localized hyperthermia-enhanced thrombolysis. Adv. Funct. Mater. 27:1701824. doi: 10.1002/adfm.201701824
Zhang, W., Deng, G., Li, B., Zhao, X., Ji, T., Song, G., et al. (2018). Degradable rhenium trioxide nanocubes with high localized surface plasmon resonance absorbance like gold for photothermal theranostics. Biomaterials 159, 68–81. doi: 10.1016/j.biomaterials.2017.12.021
Keywords: photothermal therapy, magnetocaloric therapy, thrombosis, iron sulfide, magnetic resonance imaging
Citation: Fu D, Liu J, Ren Q, Ding J, Ding H, Chen X and Ge X (2019) Magnetic Iron Sulfide Nanoparticles as Thrombolytic Agents for Magnetocaloric Therapy and Photothermal Therapy of Thrombosis. Front. Mater. 6:316. doi: 10.3389/fmats.2019.00316
Received: 15 October 2019; Accepted: 20 November 2019;
Published: 03 December 2019.
Edited by:Ming Ma, Shanghai Institute of Ceramics (CAS), China
Reviewed by:Xijian Liu, Shanghai University of Engineering Sciences, China
Jinbao Qin, Shanghai Ninth People's Hospital, China
Copyright © 2019 Fu, Liu, Ren, Ding, Ding, Chen and Ge. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
†These authors have contributed equally to this work